# Verdict: clear_cell_sarcoma_soft_tissue.md (re-verification, round 3)

1. DOSE LEAK: none. Only digits in the file are gene/fusion names (EWSR1-ATF1, EWSR1-CREB1), a tumor-size figure ("under 5 cm", matches DeVita's "<5 cm at diagnosis") and a 5-year-survival figure ("roughly half"/"~50%"), IHC marker names (S100, HMB-45), and the citation's "12th ed." No mg, mg/m2, AUC, Gy, or numbered cycle/schedule tokens anywhere.

2. UNGROUNDED / MISLABELLED CLAIMS: none found — the one item open after round 2 is now fixed.
   - Opening paragraph: the "rather than the BRAF/NRAS pathways of cutaneous melanoma" clause (flagged as the sole remaining issue in the round-2 verdict) is now tagged `(general oncology standard, not from DeVita's section on this disease)`, matching the adjacent immunotherapy-response caveat in the same paragraph. Re-confirmed BRAF/NRAS is not mentioned anywhere in DeVita's Clear Cell Sarcoma material (table or narrative, devita.txt ~lines 212464-212481 and ~214057-214081) — tag is correctly applied.
   - Same paragraph's historical-name clause ("malignant melanoma of soft parts") also correctly carries the tag.
   - EWSR1-ATF1 (>75%) / EWSR1-CREB1 (<5%) fusion claim: still grounded — confirmed present in DeVita's Chapter 60 translocation table (devita.txt ~line 212475: "EWSR1-ATF1 (>75%) / EWSR1-CREB1 (<5%)" for Clear cell sarcoma). Correctly left untagged.
   - Adjuvant RT bullet and both Monitoring/follow-up bullets (fixed in round 2): re-confirmed still tagged general-oncology-standard, untouched by this round's edit. Correct — none of these appear in DeVita's CCS section.
   - Platinum-chemo claim, antiangiogenic TKI (sorafenib/sunitinib) claim, surgical-resection/nodal-resection/sentinel-node-biopsy-debated claims, tumor size <5cm as prognostic factor, and the melanocytic IHC panel (S100, HMB-45, Melan-A): all verified directly against DeVita's Clear Cell Sarcoma prose (devita.txt ~lines 214057-214081) and correctly left untagged (they match DeVita's own wording/statistics).
   - IHC-alone-insufficient-to-distinguish clause: correctly tagged general-oncology-standard (the base IHC markers are DeVita-grounded, but the "insufficient to separate the two" inference is not stated in DeVita and is properly labelled).
   - No claim is mis-attributed to DeVita anywhere in the file.

3. CITATION: present (line 36) — "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." Name only, no page numbers. Correct.

4. VERDICT: CLEAN — ready for R1 re-review. The round-2 issue (unlabelled BRAF/NRAS contrast) is fixed and all previously-fixed items remain intact. No dose leak, no fabricated/mis-attributed claims, citation format correct.
